Researchers call for legislative reform to improve transparency in drug company payments to health care professionals
The UK's self-regulated system for disclosing payments from drug companies to health care professionals and organizations is ...
US pharma major Eli Lilly to set up GCC in Hyd
Hyderabad: The queue of global pharma giants wanting to make Hyderabad their new home for drug discovery and tech centres is ...
Afro9h
New schizophrenia drug may have milder side effects
New drug approved for treating chronic schizophrenia with fewer side effects. Could be beneficial for Black community.
C&EN10h
50 new drugs received FDA approval in 2024
The US Food and Drug Administration approved 50 new molecular entities in 2024 —just five fewer than it did in 2023. Last ...
BioSpace10h
Pharmas Turn to Licensing Deals as Risky Science Rises
Licensing deals have risen in prominence in a restrained market environment. Is it desperation, or an important part of the ...
Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market
The FDA wrapped up 2024 with 50 new drug approvals, clearing a wave of long-awaited treatments. Meanwhile, Transcarent will ...
dermatologyadvisor13h
Deucravacitinib Shows Promise in Psoriatic Arthritis Trials
Topline data were announced from two phase 3 trials evaluating deucravacitinib in adults with active psoriatic arthritis.
Sana Biotechnology: Stock Price Rise Deserved Post Diabetes Cell Therapy Success
Sana Biotechnology, Inc. shares surge as a breakthrough in diabetes therapy sparks investor interest. Click for my updated ...
Multiple Sclerosis Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Epidemiology, Therapies and Companies by DelveInsight
Multiple Sclerosis companies are Immune Response BioPharma, Clene Nanomedicine, Genzyme, ImStem Biotechnology, Rho, Inc., ...
Study identifies risk potential for thousands of mutations of a cancer gene
Scientists have characterized the role of thousands of mutations in the BRCA2 cancer gene, findings that may help reassure ...
manilatimes15h
Aer Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Fexlamose in Chronic Obstructive Pulmonary Disease
Fexlamose is being developed as a chronic treatment for COPD and asthma in conjunction with standard therapies, to improve ...
PharmiWeb17h
Cambridge Cognition highlights positive CANTAB® results in research by Bristol Myers Squib
Cambridge Cognition Holdings plc (AIM: COG), the brain health software group, congratulates Bristol Myers Squibb, the global biopharmaceutical company, for its recent FDA approval of Cobenfy (KarXT™ ...